Diagnos Inc., based in Brossard, Quebec, said it has received a Health Canada medical device licence for its CARA system. The approval marks a key regulatory step for the company and clears the way for the AI-assisted retinal image analysis platform to be offered to optometrists in Canada.
According to the announcement, DIAGNOS focuses on the early detection of eye-related health issues through artificial intelligence. CARA is intended to help eye-care professionals analyze retinal images with software support, bringing AI tools into routine optometry workflows.
For Canadian optometrists, the licence means a new approved technology is becoming available for retinal image review. The development also gives DIAGNOS a stronger position in the Canadian market as healthcare providers continue to explore AI-based tools that can support image interpretation and screening.
The news highlights the continued expansion of artificial intelligence in eye care, especially in areas tied to earlier detection and more efficient image analysis. With Health Canada authorization now in place, DIAGNOS is set to bring the CARA system to optometry practices across the country.
